SWELLABLE BIODEGRADABLE POLYMERIC MATRICES AND METHODS

• US 20120114589A1
• Filed: 10/22/2009
• Published: 05/10/2012
• Est. Priority Date: 10/22/2008
• Status: Abandoned Application

• Current Assignee: Surmodics Incorporated
• Original Assignee: Surmodics Incorporated
• Inventors: Chudzik, Stephen, Rolfes-Meyering, Emily R., Reed, Pamela J.
• Application Number:
  US13/125,521
• Publication Number:
  US 20120114589A1
• Time in Patent Office: Days
• US Class Current: 424/78.3
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: C08F 283/00 Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
• CPC Class Codes: C08F 283/06 on to polyethers, polyoxymethylenes or polyacetals C08F283/004 takes precedence
• CPC Class Codes: C08F 289/00 Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
• CPC Class Codes: C08L 2666/02 Organic macromolecular compounds, natural resins, waxes or and bituminous materials
• CPC Class Codes: C08L 51/003 grafted on to macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds C08L51/04, C08L51/06 take precedence
• CPC Class Codes: C08L 53/00 Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers

Abstract

The invention provides biodegradable polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a combination of poly-α(1→4)glucopyranose macromer and a biocompatible biostable hydrophilic macromer. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in which the matrix swells and occludes the target area, and is able to be degraded at the target site after period of time.

Claims

1. A biocompatible biodegradable swellable or swollen polymeric matrix comprising first and second polymer-containing segments crosslinked via polymerized groups, wherein the first polymer-containing segment comprises poly-α

(1→

4)glucopyranose

and the second polymer-containing segment comprises a biocompatible biostable hydrophilic polymer.

2. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein polymerized groups are pendent from the poly-α

(1→

4)glucopyranose in an amount in the range of 0.05 mmol/gram to 0.7 mmol/gram (polymerized groups/poly-α

(1→

4)glucopyranose).

4. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein the first polymer-containing segment comprises poly-α

(1→

4)glucopyranose having a molecular weight of 500,000 Da or less.

5. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment comprises an oxyalkylene polymer.

7. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment comprises a polymer selected from the group consisting of poly(ethylene oxide) (PEO), poly(ethyloxazoline), poly(propylene oxide) (PPO), poly(ethylene glycol) (PEG), and copolymers of polyethylene glycol and polypropylene oxide (PEG-PPO).

9. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment has termini, and the polymerized groups are present at the termini.

10. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment has a molecular weight in the range of 100 Da to 40 kDa.

12. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 wherein the first polymer-containing segment and the second polymer-containing segment are present in the matrix at a weight ratio in the range of 200:

1 to 1;

10, respectively.

14. The biocompatible biodegradable swellable polymeric matrix of claim 1 which is capable of swelling in water to a weight of 1.5 times or greater a weight of the matrix in a dehydrated form.

15. The biocompatible biodegradable swellable polymeric matrix of claim 1 which exerts a swelling force of 100 g/cm² or greater upon hydration from a dehydrated form.

16. The biocompatible biodegradable swellable polymeric matrix of claim 1 which is capable of swelling in water to a size that is at least 25% greater than its size in a dehydrated form.

17. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 which is associated with an implantable medical device.

18. The biocompatible biodegradable swellable or swollen polymeric matrix of claim 1 comprising a bioactive agent.

27. A method for treating a subject comprising a step of placing a biocompatible biodegradable swellable or swollen polymeric matrix according to claim 1 at a target location in a subject.

28. The method of claim 27 resulting in a swollen polymeric matrix which occludes the target location.

3. (canceled)

6. (canceled)

8. (canceled)

11. (canceled)

13. (canceled)

19. (canceled)

20. (canceled)

21. A method for forming a biocompatible biodegradable swellable or swollen polymeric matrix comprising steps of:

(a) providing a composition comprising

(i) poly-α

(1→

4)glucopyranose comprising pendent polymerizable groups, and

(ii) a biocompatible biostable hydrophilic polymer comprising a pendent polymerizable group, and

(b) activating the polymerizable groups to cause crosslinking of the poly-α

(1→

4)glucopyranose and biocompatible biostable hydrophilic polymer and matrix formation.

22. The method of claim 21 wherein the composition comprises poly-α

(1→

4)glucopyranose in an amount in the range of 50 mg/mL to about 600 mg/mL.

24. The method of claim 21 wherein the composition comprises the biocompatible biostable hydrophilic polymer in an amount in the range of 5 mg/mL to about 350 mg/mL.

26. The method of claim 21 where, in step (a) the composition is provided to a target location on a subject, and in step (b) the polymerizable groups are activated to cause crosslinking and in situ matrix formation.

29. The method of claim 26 wherein the polymeric matrix swells or is swollen at the target site, and the matrix is allowed to contact amylase for a period of time and the amylase promotes degradation of at least a portion of the matrix.

23. (canceled)

25. (canceled)